HOW CAN WE PRESCRIBE THE RIGHT TREATMENT FOR DEPRESSION?
By looking at genetics for answers.
A new centre for interdisciplinary neuroscience research is under construction at the Institute of Psychiatry and will formally open this year. The Maurice Wohl Clinical Neuroscience Institute will be home to a unique cluster of neuroscience excellence and will assist us in fast-tracking new treatments to patients.
The Institute will bring together 250 clinicians and scientists to advance our understanding of disease mechanisms and develop new therapies for neurological and psychiatric disorders through innovative research.
It will facilitate cooperation between researchers across multiple disciplines, academic institutions and healthcare organisations to dramatically accelerate the translation of basic research into clinical practice.
The Institute will be the key research facility in our efforts to fast-track new treatments to patients affected by disorders such as Alzheimer’s disease, Parkinson’s disease, motor neurone disease, epilepsy and stroke, while strengthening the College’s portfolio of internationally recognised brain research.
It possesses an unparalleled patient resource, state-of-the-art facilities and world-renowned researchers and clinicians who will be focusing on three major goals:
- Establishing the major genetic risk factors for neurodegenerative disorders
- Identifying early diagnostic tests and predictive biomarkers of diseases
Developing innovative cellular and animal disease models of disease to accelerate drug discovery
At the heart of the Institute lies a network of patients, carers, clinicians and researchers, driving forward a shared mission to improve the lives of people who live with devastating and as yet incurable disorders.
How can we understand the problems inside our heads?
How have we protected the mental health of soldiers?
How do we know which treatment will work?